Boston Scientific Corporation

BSX Healthcare Medical Devices

Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024. In the quarter to June 2026, revenue grew 7.53%, EPS grew 14.8%, free cash flow grew 13.3% and total debt rose 8.95%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

44.39 0.25 +0.57%
Market cap
$64.0B
P/E
17.9×
Fwd P/E
17.8×
Dividend yield
—
F-score
7/9
Altman Z
5.41
Beneish M
−2.49
Dividend safety
n/a

Boston Scientific Corporation (BSX) EV/FCF

Alert me on EV/FCF

As of 16 October 2026, Boston Scientific Corporation (BSX) trades at a EV/FCF of 21.3×. Over the past ten years it has ranged from 20.2× (October 2026) to 7,898× (March 2019); the current reading is higher than 1% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 41.2× (23.17%)
FY2024 53.6× 4.08%
FY2023 51.5× (33.73%)
FY2022 77.7× 52.98%
FY2021 50.8× (0.39%)
FY2020 51.0× (3.08%)
FY2019 52.6× (99.24%)
FY2018 6,964× 19,142.91%
FY2017 36.2× (13.64%)
FY2016 41.9× (38.16%)

Quarterly newest first

Period EV/FCF Change
Jun 2026 20.6× (30.19%)
Mar 2026 29.6× (28.19%)
Dec 2025 41.2× 1.60%
Sep 2025 40.5× (16.92%)
42 more quarters

Against its own ten years

Low 20.2× High 7,898×
Ten-year median 55.5×
Current reading's percentile 1

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on BSX